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Background: Guidelines for initial antiretroviral treatment (ART)
regimens have evolved, with integrase strand transfer inhibitors (INSTIs)
increasingly prominent. Research on virologic failure (VF) with INSTI
therapy is predominantly from clinical trials not care settings, especially
for recently approved medications including dolutegravir. We compared
outcomes among people living with HIV (PLWH) who initiated
recommended regimens in clinical care across the United States.
Setting: We examined 2 groups of PLWH at 8 clinics who initiated
ART regimens (August 1, 2013–March 31, 2017): those ART
treatment-naive at initiation, and those treatment-experienced.
Methods: The outcome in this longitudinal cohort study was VF,
defined as a viral load of $400 copies/mL $6 months after ART
initiation. We examined the proportion of individuals who remained
on, switched, or discontinued the regimen. Associations between
regimens and outcomes were examined with adjusted Cox pro-
portional hazards models.
Results: Among 5177 PLWH, a lower proportion experienced VF
on dolutegravir- versus other INSTI- or darunavir-based regimens
for previously treatment-naive (7% vs. 12% vs. 28%) and
treatment-experienced PLWH (6% vs. 10% vs. 21%). In adjusted
analyses, hazard ratios were similar across regimens for the
combined outcome of regimen discontinuation or treatment switch.
The hazard ratios for VF comparing dolutegravir- to darunavir-
based regimens was 0.30 (95% CI: 0.2 to 0.6) among previously
treatment-naive PLWH and was 0.60 (95% CI: 0.4 to 0.8) among
treatment-experienced PLWH.
Conclusions: The proportion of previously treatment-naive PLWH
remaining on recommended ART regimens did not differ by
regimen. The likelihood of VF was lower with dolutegravir- than
darunavir-based regimens for previously treatment-naive and
treatment-experienced PLWH.
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suppression, darunavir, integrase strand transfer inhibitors, antire-
troviral therapy, virologic failure
(J Acquir Immune Defic Syndr 2019;81:572–577)
INTRODUCTION
Treatment guidelines for initial antiretroviral treatment
(ART) regimens for people living with HIV (PLWH) have
evolved, with integrase strand transfer inhibitors (INSTIs)
increasingly prominent.1 By contrast, darunavir-based regi-
mens (a protease inhibitor) are being de-emphasized,
although still remain first-line treatment in specific
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populations (eg, those whose resistance testing is not yet
available).1 Much of the outcomes data, such as virologic
failure (VF) with INSTI, are from trials2–8 rather than more
generalizable care. In particular, less is known about VF for
the more recently approved INSTI dolutegravir in care
settings. However, there is interest in INSTI, particularly
dolutegravir, because they may have superior tolerability,
reduced pill burden, and improved outcomes.3,4,6,9–14 It has
been proposed that dolutegravir can result in viral suppres-
sion, even potentially with pre-existing INSTI muta-
tions.15,16 This is likely due, in part, to favorable
pharmacodynamic profiles, even in comparison with other
INSTI.17 Therefore, we conducted this longitudinal cohort
study to compare regimen switching and VF rates among




The CFAR Network of Integrated Clinical Systems
(CNICS) is a dynamic cohort of .32,000 PLWH attending
clinical care at 8 sites. The CNICS data repository integrates
comprehensive clinical data including laboratory test results,
ART use, diagnoses, demographic data, and historical
information, including previous ART.18 Institutional review
boards at each site approved CNICS protocols.
Study Participants
We examined 2 groups of PLWH who initiated one of
the recommended ART regimens between August 1, 2013,
and March 31, 2017: PLWH known to be ART treatment-
naive at initiation and those with previous ART exposure.
Follow-up was censored at death, regimen change, or loss to
follow-up (LTFU).
Regimen
We compared dolutegravir versus other recommended
INSTI- versus darunavir-based regimens included in contem-
porary guidelines for initiating ART. We were interested in 3
regimen categories.
• Dolutegravir-based: dolutegravir/abacavir/lamivudine OR
dolutegravir/tenofovir/emtricitabine
• Other recommended INSTI-based: raltegravir/tenofovir/
emtricitabine OR elvitegravir/cobicistat/tenofovir/emtricitabine
• Darunavir/ritonavir/tenofovir/emtricitabine
selected this cutoff, given the increased mortality associated
with viremia at levels as low as 400 copies/mL.19 We
repeated analyses using $200 copies/mL to define VF.1 In
addition, we examined the proportion who remained on,
switched, or discontinued regimens. We defined switching in
2 ways: (1) any change to any regimen component whether or
not it resulted in a regimen outside the initial regimen
category and (2) any change to the anchor medication
resulting in a regimen not part of the initial regimen category
(as in previously published studies20). For example, changing
from dolutegravir/tenofovir/emtricitabine to dolutegravir/
abacavir/lamivudine would be a switch with the first defini-
tion but not the second.
Statistical Analyses
We used x2 tests for categorical variables and t-tests
for continuous variables to assess differences in demo-
graphic and clinical characteristics by regimen category. To
examine VF and treatment switching during follow-up, we
used Cox proportional hazards models, adjusting for age,
sex, race/ethnicity, hepatitis B, hepatitis C, tuberculosis,
HIV transmission risk factor, CD4 count at treatment
initiation, HIV viral load, days from baseline HIV viral
load until ART initiation, and site. Because of insufficient
numbers, tuberculosis and hepatitis B were dropped from
smaller analyses (previously treatment-naive PLWH).
Among previously treatment-experienced individuals, we
also adjusted for previous INSTI use. Sensitivity analyses
varied LTFU censoring definitions from 0 to 12 months after
last activity and included or excluded inverse probability
censoring weights based on the same variables in the main
models.21
RESULTS
We observed 1280 treatment-naive and 3897 pre-
viously treatment-experienced PLWH from CNICS sites
across the United States who initiated recommended regi-
mens. Table 1 shows demographic and clinical character-
istics by regimen and previous treatment experience.
Patients who initiated a dolutegravir-based regimen were,
on average, slightly older, and more likely female among
previously treatment-naive but not treatment-experienced
individuals, and more likely to have hepatitis C among
treatment-experienced individuals (Table 1). In addition,
among those who were treatment-experienced, mean CD4
count at initiation was lower, and the percentage with a viral
load $100,000 was higher among those on darunavir
(Table 1).
Treatment-Naive at Regimen Initiation
Among treatment-naive PLWH at regimen initiation,
the percentage who started and remained on dolutegravir-
based regimens was similar to those on other INSTI- or
darunavir-based regimens (74%–79%) (Table 2). The per-
centage who switched regimens (all changes) was also similar
among those on dolutegravir- versus other INSTI- or
We did not distinguish between lamivudine and 
emtricitabine or between tenofovir formulations [most of 
which were tenofovir disoproxil fumarate (TDF)] (see Table 
1, Supplemental Digital Content, http://links.lww.com/QAI/
B321 for distribution of regimens).
Outcomes
The primary outcome was VF, defined as a viral load of
$400 copies/mL $6 months after regimen initiation. We
TABLE 1. Demographic and Clinical Characteristics at Initiation of Regimen by Regimen Type for People Living With HIV Who
Were Previously Treatment-Naive and Those Who Were Treatment-Experienced
Characteristic




























679 (88) 79 (98) ,0.001 1605 (78) 1157 (78) 270 (76) 0.6
Female
77 (18)




273 (35) 28 (35) 0.2 931 (45) 577 (39) 104 (29) ,0.001
Black
191 (45)
373 (48) 31 (38) 839 (41) 689 (46) 211 (59)
Hispanic
39 (9)
69 (9) 14 (17) 212 (10) 158 (11) 30 (8)
Other
36 (8)
58 (8) 8 (10) 72 (4) 62 (4) 12 (3)
HIV transmission risk factor, N (%)
MSM
239 (56)
508 (66) 53 (65) 0.03 1054 (51) 813 (55) 157 (44) ,0.001
Injection drug user
43 (10)
56 (7) 10 (12) 362 (18) 178 (12) 70 (20)
Heterosexual
119 (28)
171 (22) 15 (19) 582 (28) 448 (30) 121 (34)
Other/unknown
25 (6)
38 (5) 3 (4) 56 (3) 47 (3) 9 (3)
Hepatitis B, N (%)
Yes
11 (3)
26 (3) 2 (2) 0.7 95 (5) 73 (5) 28 (8) 0.04
No
415 (97)
747 (97) 79 (98) 1959 (95) 1413 (95) 329 (92)
Hepatitis C, N (%)
Yes
42 (10)
49 (6) 13 (16) 0.003 427 (21) 190 (13) 66 (18) ,0.001
No
384 (90)
724 (94) 68 (84) 1627 (79) 1296 (87) 291 (82)
Time in care before starting
regimen, mean (SD), yr 1.0 (2.8)
0.6 (1.9) 0.8 (2.1) 0.02 7.7 (5.7) 5.9 (5.4) 6.1 (5.4) ,0.001
CD4 at regimen initiation, mean
(SD), cells/mm3 370 (256)
397 (278) 388 (262) 0.2 593 (347) 557 (325) 428 (298) ,0.001




524 (68) 55 (68) 1.0 1956 (95) 1375 (93) 316 (89) ,0.001
$100,000
135 (32)
249 (32) 26 (32) 98 (5) 111 (7) 41 (11)
*This includes dolutegravir/abacavir/emtricitabine and dolutegravir/tenofovir/emtricitabine.
†This includes elvitegravir/cobicistat/tenofovir/emtricitabine and raltegravir/tenofovir/emtricitabine.
MSM, men who have sex with men.
darunavir-based regimens (15%, 12%, 16%, respectively). 
However, of dolutegravir users who switched regimens, 32%
changed to another dolutegravir-based recommended regimen 
(Triumeq: dolutegravir/abacavir/lamivudine). The proportion
who experienced VF differed across regimens; it was lower 
for those who initiated dolutegravir- versus other INSTI- or 
darunavir-based regimens (7%, 12%, 28%, respectively)
(Table 2).
Adjusted Analyses: Virologic Failure
The aHR for VF did not differ between dolutegravir-
based versus other INSTI-based regimens, but it was lower
for dolutegravir-based versus darunavir-based regimens
among previously treatment-naive (0.30; 95% CI: 0.2 to
0.6) and treatment-experienced (0.60; 95% CI: 0.4 to 0.8)
individuals (see Table 2, Supplemental Digital Content, http://
links.lww.com/QAI/B321). In the adjusted models, demo-
graphic and clinical characteristics had little association with
VF in previously treatment-naive individuals; however,
factors such as younger age, black race, previous INSTI
use, and lower CD4 count were associated with VF in some
treatment-experienced comparisons (see Table 3, Supplemen-
tal Digital Content, http://links.lww.com/QAI/B321 shows
full model results for dolutegravir vs. darunavir models for
previously treatment-naive vs. experienced PLWH). We
conducted sensitivity analyses defining VF as $200
copies/mL, and results were similar (see Table 2, Supple-
mental Digital Content, http://links.lww.com/QAI/B321). In
sensitivity analyses examining VF with varying censoring
definitions, the aHR was consistently significantly lower for
dolutegravir- versus darunavir-based regimens. By contrast,
the aHR for VF for dolutegravir- versus other INSTI-based
regimens varied (0.7–1.2) depending on censoring definitions
for LTFU with both significant and nonsignificant associa-
tions. Results from sensitivity analyses with inverse proba-
bility weighting for censoring were similar to results from
models without inverse probability weighting (data
not shown).
DISCUSSION
This study found that the proportion of PLWH in
clinical care in the United States who remained on recom-
mended ART regimens did not differ by regimen during
TABLE 2. Outcomes by Regimen Type for People Living With HIV Who Were Previously Treatment-Naive and Those Who Were
Treatment-Experienced
Characteristic
























Duration of follow-up, mean (SD), d 342 (283) 494 (353) 564 (422) ,0.001 367 (286) 430 (336) 436 (341) ,0.001
Remained on regimen, N (%) 316 (74) 601 (78) 64 (79) 0.3 1526 (74) 1018 (69) 212 (59) ,0.001
Experienced VF, ($400 copies/mL)
N (%)
28 (7) 93 (12) 23 (28) ,0.001 115 (6) 152 (10) 75 (21) ,0.001
Died, N (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Discontinued regimen, N (%) 44 (10) 79 (10) 4 (5) 0.3 226 (11) 192 (13) 66 (18) ,0.001
Switched regimen (all changes),
N (%)
66 (15) 93 (12) 13 (16) 0.2 302 (15) 276 (19) 79 (22) ,0.001
Switched from regimen (but
remained in category), N (%)
21 (32) 1 (1) 0 (0) ,0.001 55 (18) 15 (5) 0 (0) ,0.001
Switched regimen (switch resulted in
new category), N (%)
45 (68) 92 (99) 13 (100) ,0.001 247 (82) 261 (95) 79 (100) ,0.001
*This includes dolutegravir/abacavir/emtricitabine and dolutegravir/tenofovir/emtricitabine.
†This includes elvitegravir/cobicistat/tenofovir/emtricitabine and raltegravir/tenofovir/emtricitabine.
Treatment Experienced at Regimen Initiation
The percentage of treatment-experienced individuals 
who remained on their regimens was highest for dolutegravir-
(74%) and lowest for darunavir-based regimens (59%) (Table 
2). The percentage who switched regimens was lower among 
those on dolutegravir- versus other INSTI- or darunavir-based 
regimens (15%, 19%, 22%, respectively). Furthermore, 18%
of those who were treatment-experienced and switched 
regimens from a dolutegravir-based regimen changed to 
another recommended dolutegravir-based regimen. A lower 
proportion experienced VF among those on dolutegravir-
versus other INSTI- or darunavir-based regimens (6%, 10%, 
21%, respectively).
Adjusted Analyses: Regimen Discontinuation 
or Treatment Switch
For the combined outcome of regimen discontinuation 
or treatment switch, defined as changing any component of 
a regimen, the adjusted hazard ratios (aHRs) for previously 
treatment-naive PLWH were higher for dolutegravir- versus 
other INSTI-based regimens [1.42; 95% confidence interval 
(CI): 1.1 to 1.8] but not versus darunavir-based regimens 
(1.23; 95% CI: 0.7 to 2.2). Among treatment-experienced 
PLWH, the aHR was not different for dolutegravir-based 
versus other INSTI-based (0.91; 95% CI: 0.8 to 1.04) or 
darunavir-based (1.12; 95% CI: 0.9 to 1.4) regimens. When 
the switching definition excluded changes to the same anchor 
within the same regimen category, the aHR for dolutegravir 
was lower than for other INSTI-based regimens (0.84; 95%
CI: 0.7 to 0.96) for treatment-experienced, but not treatment-
naive PLWH (1.07; 95% CI: 0.8 to 1.4); other regimen 
category comparisons were not significant.
follow-up for previously treatment-naive individuals. How-
ever, among treatment-naive and treatment-experienced in-
dividuals, those initiating dolutegravir-based regimens were 
more likely when changing regimens to remain on the same 
anchor (dolutegravir), suggesting regimen simplification 
rather than dolutegravir intolerance, which was in contrast 
to switches from other regimens. In unadjusted analyses, we 
found differences in the proportion who experienced VF by 
regimen: a lower proportion on dolutegravir-based regimens 
experienced VF compared with those on other INSTI- or 
darunavir-based regimens. In adjusted analyses, PLWH 
initiating dolutegravir-based regimens were less likely to 
experience VF than those starting darunavir-based regimens, 
regardless of previous treatment status.
These findings build on trials of ART-naive and 
treatment-experienced PLWH that suggested dolutegravir 
may be superior to other recommended anchors,2,5 but not 
consistently.3 For example, the SAILING trial of treatment-
experienced PLWH with ART resistance found a larger 
proportion randomized to dolutegravir versus raltegravir had 
viral suppression at week 48.2 In the FLAMINGO trial of 
ART-naive individuals, viral suppression rates were 68%
versus 80% in the darunavir versus dolutegravir arms at 96 
weeks.4,5 By contrast, SPRING-2 found no significant 
difference in the percentages of treatment-naive PLWH with 
viral suppression who received dolutegravir (88%) versus 
raltegravir (85%) at 48 weeks.3 A systematic review con-
cluded that darunavir-based regimens were inferior to dolute-
gravir- and raltegravir-based regimens at 96 weeks.22 
Similarly, a meta-analysis found small but significant supe-
riority of dolutegravir- versus raltegravir- or elvitegravir-
based regimens.23 Although trial results do not always 
generalize well to the diverse populations of PLWH in 
clinical care, they have suggested potential benefits of 
dolutegravir over other recommended regimen options.
This study builds on clinical care studies that compared 
dolutegravir-based regimens with others. However, several of 
these studies included small numbers on dolutegravir24–29 or 
were single-center design, limiting generalizability24,26–29; or  
they lacked comparison arms,24,28,29 limiting conclusions. 
One study compared PLWH on dolutegravir who had pre-
existing nucleoside reverse transcriptase inhibitor mutations 
to those on one of several protease inhibitors and found 
similarly low VF rates.25 However, with only 122 individuals 
in each of the 2 groups (including a mixture of protease 
inhibitors as well as a mix of some suppressed at initiation 
and some not), conclusions are limited. One of the largest 
studies to date included 739 treatment-naive and 352 
treatment-experienced individuals receiving care at the Hos-
pital Clinic of Barcelona and suggested that discontinuations 
might be lower among elvitegravir users, although questions 
were raised regarding whether this difference was due to 
elvitegravir-based regimens always being available in a single 
pill, with changes in other regimens potentially due to 
regimen simplification.20
We found a higher switching rate for all regimens, 
including dolutegravir (eg, 12%–16% among previously 
treatment-naive individuals), than might be expected given 
the low rates (eg, 3%–11%) of discontinuing or switching
because of toxicities in clinical trials.2,7 However, observed 
rates are more consistent with the limited data available from 
care settings.30 Previous studies questioned whether neuro-
psychological side-effects associated with dolutegravir could 
have led to increased discontinuation and whether this was 
more common among abacavir users.30 It was hypothesized 
that this is due to both drugs being metabolized by the same 
enzyme (UDP-glucuronosyltransferase). However, others 
have disputed this by evaluating plasma trough dolutegravir 
levels among abacavir users and nonusers.31 Questions 
regarding whether integrase inhibitors may be associated 
with weight gain have also been raised.32 We do not capture 
complete reasons for stopping or switching regimens; how-
ever, we did not see differences in rates among dolutegravir 
users with (23%) or without (27%) abacavir. We found 
similar switching rates among previously treatment-naive 
PLWH on dolutegravir and other INSTI until we excluded 
switching within category. All changes from one dolutegravir 
regimen to another were switches to Triumeq (dolutegravir/
abacavir/lamivudine) suggesting simplification given the 
change to a single pill-per-day regimen. This is consistent 
with a previous Australian study that noted switching to 
dolutegravir/abacavir/lamivudine was most often regimen 
simplification.33
Despite limiting analyses to 2013 or after, when all 
regimens of interest were available, LTFU for initiators of 
older regimens was higher (darunavir) than it was for 
dolutegravir initiators, in part, because dolutegravir was often 
started more recently. We censored follow-up at last activity 
date for primary analyses to prevent bias because of inclusion 
of person-time during which an event could not occur, to 
provide the most unbiased estimates possible for laboratory 
outcomes.34 We followed the guidance of Lesko et al34 who 
demonstrated that the potential bias if this is not performed 
can be substantial as well as unpredictable in magnitude and 
direction. Sensitivity analyses with different LTFU definitions 
revealed some variations in results, highlighting the impor-
tance of this decision, particularly for analyses focused on 
newer regimens such as those containing dolutegravir.
This study has several strengths and limitations. It 
was limited to PLWH who initiated regimens starting 
August 2013 and after to ensure all regimens of interest 
were available. While this enhances comparability across 
regimens, it decreases follow-up time. Furthermore, chan-
neling bias always remains a concern. We lacked sufficient 
numbers to distinguish those on TDF (majority of individ-
uals with tenofovir in their regimen) vs. those on the more 
recently approved tenofovir alafenamide (TAF). The 
diverse population is a strength, as clinical trials do not 
necessarily represent populations of PLWH,35 but CNICS 
may not generalize to all PLWH in less-resourced US 
settings or other regions of the world. The data used for this 
study came from routine care. There were variable lengths 
of time between follow-up visits and clinical tests. 
Therefore, the timing of VF could be misclassified, for 
example, if a patient’s viral load increased, but the patient 
was not seen right away in the clinic and tested. However, 
it is unlikely that this would occur differentially 
by regimen.
CONCLUSIONS
This study demonstrated that the proportion that
remained on recommended dolutegravir-based regimens was
similar to those on INSTI- and darunavir-based regimens for
previously treatment-naive PLWH. While switching regimens
was common in all categories, dolutegravir users were more
often “switched” to another dolutegravir-based regimen with
fewer pills, presumably for regimen simplification. PLWH on
dolutegravir-based regimens, whether previously treatment-
naive or treatment-experienced, were less likely to experience
VF than those on darunavir-based regimens.
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